Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metronomic neoadjuvant capecitabine and cyclophosphamide in high-PCI pseudomyxoma peritonei
2024-514329-42-00Phase 2Authorised
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Sep 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine and cyclophosphamide in pseudomyxoma peritonei (PMP), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: Completeness of cytoreduction. Planned start Sep 2024; status: authorised.
02
Drugs
capecitabinecyclophosphamide
03
Conditions
pseudomyxoma peritonei (PMP)
Beyond the preview
Go deeper on 2024-514329-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514329-42-00.